Mode
Text Size
Log in / Sign up

Artificial Intelligence Performance in Dermatoscopic Image Interpretation for Skin Cancer DiagnosisAI Shows High Performance in Detecting Skin Cancer Images

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
AI shows high diagnostic performance for melanoma and basal cell carcinoma compared to standard dermatoscopic assessment.

This systematic review and meta-analysis evaluates the diagnostic performance of artificial intelligence (AI) when interpreting dermatoscopic images. The study specifically focuses on identifying melanoma, basal cell carcinoma, and squamous cell carcinoma to determine if automated systems outperform traditional methods.

Results indicate that AI demonstrates high diagnostic performance for melanoma when compared to dermatoscopic assessment alone by clinicians. Furthermore, AI showed high performance in identifying basal cell carcinoma or malignancy, suggesting significant potential for integration into screening workflows.

While AI showed higher sensitivity for melanoma than manual clinical methods, the data regarding its superiority for basal cell carcinoma and squamous cell carcinoma remains inconclusive. Reflectance confocal microscopy also showed high sensitivity for diagnosing cutaneous malignancies.

Integrating AI into clinical practice may significantly reduce resource burdens, particularly in primary care settings. While not yet proven superior in all categories, AI serves as a valuable tool to assist clinicians in making accurate diagnoses and managing patient volume efficiently.

How this fits prior evidence

This meta-analysis addresses a gap in the technological tools available for skin cancer screening. While prior coverage has established the high prevalence of primary resistance to PD-1 monotherapy in 40% to 55% of advanced melanoma patients and the role of the MITF E318K variant in melanoma risk, this study focuses on diagnostic accuracy. It provides evidence on how AI might assist in the initial identification of malignancies like melanoma and basal cell carcinoma.

A review of 208 articles looked at how artificial intelligence (AI) performs when interpreting dermatoscopic images. These are specialized images used to look at skin conditions. The study compared AI performance against traditional methods where clinicians or experts look at the images alone or in combination with a physical exam.

The findings show that AI had high diagnostic performance for identifying melanoma and basal cell carcinoma. In some cases, AI showed higher sensitivity for melanoma than when doctors combined clinical exams with skin images. However, the results were not clear regarding whether AI was more sensitive than human experts for identifying squamous cell carcinoma or basal cell carcinoma when both were assessed together.

While the technology shows promise, it is still being evaluated. The study suggests that AI could help reduce the workload for healthcare providers and assist doctors in primary care settings. Because the evidence for certain skin cancers is not yet fully clear, these tools are currently seen as a way to support, rather than replace, clinical judgment.

What this means for you:
AI shows high accuracy in detecting melanoma and some other skin cancers in images, potentially aiding doctors.

Common questions

How accurate is AI at detecting melanoma?

The review of 208 articles found that artificial intelligence showed high diagnostic performance for melanoma when compared to clinicians or experts looking at dermatoscopic images alone. In some cases, AI showed higher sensitivity for melanoma than when doctors combined a physical exam with skin images.

Can AI identify other types of skin cancer?

The study found that AI had high diagnostic performance for basal cell carcinoma. However, it was not clear if AI was more sensitive than a combination of clinical and dermatoscopic assessment for diagnosing basal cell carcinoma or squamous cell carcinoma.

How can AI help in a doctor's office?

AI could potentially help reduce the resource burden on healthcare providers. It may serve as a helpful tool to assist doctors during clinical assessments, especially in primary care settings where resources may be limited.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BACKGROUND: Skin cancer is one of the most prevalent malignancies worldwide, particularly within Caucasian populations. This systematic review and meta-analysis aimed to quantitatively review the current literature on non-invasive diagnosis of skin cancer and evaluate the current evidence to support the use of tools in addition to, or in replacement of clinician face-to-face assessment. METHODS: A literature search was conducted for publications in PubMed, Medline and Embase databases. Articles describing accuracy, sensitivity, specificity and outcomes of their mode of assessment were included. A total of 208 articles met the inclusion criteria. RESULTS AND CONCLUSION: This systematic review and meta-analysis showed that the diagnostic performance of artificial intelligence (AI) in the interpretation of dermatoscopic images was high for melanoma diagnosis, basal cell carcinoma or malignancy, in comparison to dermatoscopic assessment alone by clinicians and experts. Although AI interpretation of images demonstrated higher sensitivity for melanoma diagnosis in comparison to clinical assessment combined with dermatoscopic assessment, it is unclear if this is also the case for basal cell carcinoma and squamous cell carcinoma diagnosis. Reflectance confocal microscopy, a non-invasive high resolution imaging technique, is known to have a high sensitivity for diagnosing cutaneous malignancy, and this may have applications within secondary care. Therefore, AI could help reduce resource burden and aid in clinical assessment, particularly within primary care settings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.